HK1128929A1 - Pegylated mutated clostridium botulinum toxin - Google Patents

Pegylated mutated clostridium botulinum toxin

Info

Publication number
HK1128929A1
HK1128929A1 HK09108510.5A HK09108510A HK1128929A1 HK 1128929 A1 HK1128929 A1 HK 1128929A1 HK 09108510 A HK09108510 A HK 09108510A HK 1128929 A1 HK1128929 A1 HK 1128929A1
Authority
HK
Hong Kong
Prior art keywords
modified
botulinum toxin
chain
tag
exhibits
Prior art date
Application number
HK09108510.5A
Other languages
English (en)
Chinese (zh)
Inventor
Jrgen Frevert
Volker Specht
Original Assignee
莫茨藥物股份兩合公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 莫茨藥物股份兩合公司 filed Critical 莫茨藥物股份兩合公司
Publication of HK1128929A1 publication Critical patent/HK1128929A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
HK09108510.5A 2006-03-15 2009-09-17 Pegylated mutated clostridium botulinum toxin HK1128929A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06005300A EP1834962A1 (de) 2006-03-15 2006-03-15 PEGyliertes mutiertes Clostridium botulinum Toxin
PCT/EP2007/002296 WO2007104567A2 (de) 2006-03-15 2007-03-15 Pegyliertes mutiertes clostridium botulinum toxin

Publications (1)

Publication Number Publication Date
HK1128929A1 true HK1128929A1 (en) 2009-11-13

Family

ID=36603470

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108510.5A HK1128929A1 (en) 2006-03-15 2009-09-17 Pegylated mutated clostridium botulinum toxin

Country Status (17)

Country Link
US (4) US8003601B2 (xx)
EP (2) EP1834962A1 (xx)
JP (1) JP5232021B2 (xx)
KR (1) KR101454273B1 (xx)
CN (1) CN101432296B (xx)
AT (1) ATE443078T1 (xx)
AU (1) AU2007224669B2 (xx)
BR (1) BRPI0708907A2 (xx)
CA (1) CA2638862A1 (xx)
DE (1) DE502007001546D1 (xx)
ES (1) ES2334283T3 (xx)
HK (1) HK1128929A1 (xx)
IL (1) IL193777A (xx)
MX (1) MX2008011495A (xx)
RU (1) RU2426739C2 (xx)
WO (1) WO2007104567A2 (xx)
ZA (1) ZA200807284B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
WO2009150470A2 (en) 2008-06-12 2009-12-17 Syntaxin Limited Suppression of cancers
EP2310028B1 (en) 2008-06-12 2016-11-16 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of acromegaly
EP2337790B1 (en) * 2008-08-29 2016-07-13 Merz Pharma GmbH & Co. KGaA Clostridial neurotoxins with altered persistency
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
ES2600463T3 (es) * 2010-05-20 2017-02-09 Allergan, Inc. Toxinas clostridiales degradables
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
EP2952205B1 (en) 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
EP3215172B1 (en) * 2014-11-07 2023-04-26 Kineta Chronic Pain, Llc. Modifications and uses of conotoxin peptides
SG11201705019PA (en) 2014-12-23 2017-07-28 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
CN109153712B (zh) 2016-04-19 2022-09-16 格里芬制药国际公司 Peg化生物活性肽及其用途
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
CA3077215A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. Porcine g-csf variants and their uses
CA3220194A1 (en) 2018-01-29 2019-08-01 Ipsen Biopharm Limited Non-neuronal snare-cleaving botulinum neurotoxins
EP3752128A1 (de) * 2018-02-16 2020-12-23 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
US11975055B2 (en) 2018-05-21 2024-05-07 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815844D0 (en) 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
WO2021150581A2 (en) * 2020-01-21 2021-07-29 Trustees Of Dartmouth College Immunologically optimized botulinum toxin light chain variants
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (de) 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
AU2005279741B2 (en) * 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
EP1834962A1 (de) * 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin

Also Published As

Publication number Publication date
US9186396B2 (en) 2015-11-17
WO2007104567A3 (de) 2007-11-01
RU2008140368A (ru) 2010-04-20
CA2638862A1 (en) 2007-09-20
EP1994048B1 (de) 2009-09-16
CN101432296B (zh) 2014-07-02
US20090118193A1 (en) 2009-05-07
IL193777A (en) 2011-09-27
IL193777A0 (en) 2011-08-01
RU2426739C2 (ru) 2011-08-20
EP1834962A1 (de) 2007-09-19
WO2007104567A2 (de) 2007-09-20
KR101454273B1 (ko) 2014-10-28
AU2007224669A1 (en) 2007-09-20
JP2009531026A (ja) 2009-09-03
US8003601B2 (en) 2011-08-23
US8912140B2 (en) 2014-12-16
ES2334283T3 (es) 2010-03-08
US20150166977A1 (en) 2015-06-18
JP5232021B2 (ja) 2013-07-10
BRPI0708907A2 (pt) 2011-06-21
AU2007224669B2 (en) 2010-05-13
EP1994048A2 (de) 2008-11-26
US20110294747A1 (en) 2011-12-01
US8298550B2 (en) 2012-10-30
DE502007001546D1 (de) 2009-10-29
MX2008011495A (es) 2008-09-24
ATE443078T1 (de) 2009-10-15
CN101432296A (zh) 2009-05-13
ZA200807284B (en) 2009-04-29
US20130156747A1 (en) 2013-06-20
KR20080106451A (ko) 2008-12-05

Similar Documents

Publication Publication Date Title
ZA200807284B (en) Pegylated mutated clostridium botulinum toxin
UA103215C2 (uk) Поліпептид з ксиланазною активністю
WO2007018619A3 (en) Chimeric therapeutic agents
IL187293A0 (en) Recombinant n-glycosylated proteins from procaryotic cells
UA103216C2 (uk) Поліпептид з ксиланазною активністю
PE20120021A1 (es) Mutantes fgf21
EA200702408A1 (ru) Аналоги глюкагонподобного пептида-2 (glp-2)
UA102506C2 (ru) Селективные аналоги глюкагоноподобного пептида-2 (glp-2)
WO2007035600A3 (en) Natriuretic activities
UA94244C2 (ru) Анти-cgrp антагонистическое антитело и фармацевтическая композиция, которая его включает
WO2011068953A3 (en) Atoxic recombinant holotoxins of clostridium difficile as immunogens
TW200722436A (en) A peptide-immunoglobulin-conjugate
WO2009025117A1 (ja) Cdca1ペプチド及びこれを含む薬剤
NZ607069A (en) Modified relaxin polypeptides and their uses
ATE536367T1 (de) Bindende peptidomimetika und deren verwendungen
NZ602702A (en) Modified fgf-21 polypeptides and their uses
WO1999003881A3 (fr) Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
NZ594268A (en) Grass peptides for vaccine
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
ATE548380T1 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
EP1982992A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
WO2006122205A3 (en) Conus californicus neurotoxins
Ghosh et al. A novel method for sequence independent incorporation of activated/protected cysteine in Fmoc solid phase peptide synthesis
MXPA03008438A (es) Toxina insecticida de bacillus thuringiensis modificada sensible a pepsina.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180315